Despite YiChang HEC ChangJiang Pharmaceutical's decent ROE hinting at promising fundamentals, its low earnings growth remains a concern, primarily considering it reinvests a significant part of profits. External factors might be inhibiting growth, but future earnings growth is predicted to dramatically improve.